Search
News
indie Q2 2026 Earnings: Revenue Rises 24% as Losses Narrow
indie Semiconductor’s Q2 2026 revenue rose 24% year over year to $64.0 million, while its GAAP operating loss narrowed to $35.1 million from $43.0 million. Adjusted EBITDA improved to a $6.5 million loss from a $12.5 million loss, although the company remained below break-even. For Q3 2026, indie guided to $67 million to $73 million of revenue, with the $70 million midpoint implying 30% growth and an expected mix of roughly $40 million from the core business and $30 million from Wuxi indie Micro.
TradingKey
Thu, Aug 6
Concentra Q2 2026 earnings: Operating leverage lifts profit and cash flow
Concentra (NYSE: CON) reported Q2 2026 revenue of $606.0 million, up 10.0% year over year, while diluted EPS rose to $0.51 from $0.35. Adjusted EBITDA increased 22.5% to $140.9 million, and free cash flow nearly doubled to $121.0 million as higher earnings, working-capital timing and lower capital spending supported cash generation. Daily patient visits and revenue per visit both increased, and the company raised its full-year outlook while outlining a planned CEO transition for November 2026.
TradingKey
Thu, Aug 6
Chesapeake Utilities Q2 2026 earnings: Regulated growth supports a modest EPS gain
Chesapeake Utilities’ Q2 2026 revenue increased 4.7% to $201.9 million, while GAAP diluted EPS rose to $1.05 from $1.02 and net income reached $25.4 million. Regulated Energy and transmission and infrastructure projects drove adjusted gross margin to $150.2 million, up 5.2%, but higher operating costs, interest expense and a larger share count limited per-share growth. The company also raised 2026 capital spending guidance by $100 million to $550 million-$600 million as project activity accelerated.
TradingKey
Thu, Aug 6
Relay Therapeutics Q2 2026 earnings: Clinical spending rises with cash runway into 2029
Relay Therapeutics’ Q2 2026 revenue fell to $0.4 million from $0.7 million, while net loss widened to $83.7 million and loss per share remained $0.41. R&D expense rose 20% to $76.5 million as spending increased across zovegalisib clinical trials. Cash, cash equivalents and investments reached $910.9 million after the May follow-on offering, supporting an expected runway into 2029. Relay also reported a 44% response rate for a zovegalisib triplet in heavily pretreated breast cancer patients and opened vascular-anomaly expansion cohorts.
TradingKey
Thu, Aug 6
DoubleVerify Q2 2026 earnings: Cost control lifts margins on 3% revenue growth
DoubleVerify’s Q2 2026 revenue rose 3% year over year to $193.8 million, while diluted GAAP EPS increased to $0.08 from $0.05. Adjusted EBITDA reached $65.3 million and margin expanded to 34% from 30% as operating expenses declined. Measurement revenue grew 6% and Supply-Side revenue rose 13%, offsetting a 1% decline in Activation. Quarterly free cash flow increased to $65.7 million, although first-half free cash flow remained below the prior-year period. DV also agreed to be acquired by Nielsen and withdrew its previous financial guidance while the transaction is pending.
TradingKey
Thu, Aug 6
Casella Waste Q2 2026 earnings: acquisitions lift revenue as margins narrow
Casella Waste Systems’ Q2 2026 revenue rose 16.9% to $543.7 million, supported by acquisitions, pricing and higher landfill volumes. Adjusted EBITDA increased 12.5% to $123.2 million, but the margin narrowed to 22.7% from 23.5% as elevated fuel costs created a 40-basis-point headwind despite recovery fees. GAAP net income fell 27.6% to $3.8 million. For 2026, Casella raised revenue guidance, lowered net income guidance, and reaffirmed its adjusted EBITDA and cash flow ranges, leaving acquisition integration, leverage and margin conversion as the main operating issues.
TradingKey
Thu, Aug 6
Arteris Q2 2026 earnings: Revenue rose 46% while losses widened
Arteris reported Q2 2026 revenue of $24.1 million, up 46% year over year, while its GAAP net loss widened to $14.1 million, or $0.30 per share. ACV plus royalties reached $99.5 million, up 44%, and RPO climbed 36% to $135 million, indicating stronger contracted activity. However, GAAP gross margin fell to 85% from 89% and operating expenses increased, pushing the operating loss to $13.9 million. Quarterly free cash flow improved to $8.6 million, while updated 2026 guidance calls for revenue of $95 million to $98 million.
TradingKey
Thu, Aug 6
INmune Bio Q2 2026 earnings: Tax rebate benefit narrows net loss
INmune Bio’s Q2 2026 earnings showed no revenue, a net loss of $1.3 million versus $24.5 million a year earlier, and diluted EPS of -$0.05 versus -$1.05. The narrower loss mainly reflected an Australian R&D tax rebate benefit and the absence of the prior-year $16.5 million impairment, rather than commercial sales. Cash was $18.4 million at June 30, while Ebstrocel advanced toward UK and U.S. filings and XPro received FDA Fast Track designation following Phase 2 biomarker findings in early Alzheimer’s disease.
TradingKey
Thu, Aug 6
Organogenesis Q2 2026 earnings: Wound care decline compresses margins
Organogenesis reported Q2 2026 net product revenue of $42.8 million, down 58% year over year, as Advanced Wound Care revenue fell 61%. Gross margin contracted to 45% from 73%, diluted loss per share widened to $0.77 from $0.10, and adjusted EBITDA loss reached $34.4 million. The company ended June with $46.8 million in cash, cash equivalents and restricted cash and revised full-year net revenue guidance to $179 million-$215 million as the expected market recovery proceeds more slowly.
TradingKey
Thu, Aug 6
Red Cat Q2 2026 Earnings: Revenue Jumps but Losses Widen
Red Cat (NASDAQ: RCAT) reported Q2 2026 revenue of $20.2 million, up 527% year over year, while diluted loss per share widened to $0.26 from $0.15. Gross margin improved to 16.1%, but operating expenses rose to $41.9 million and the net loss expanded to $35.3 million. Cash reached $325.6 million after substantial equity financing, even as first-half operating cash outflow was $78.7 million and inventory climbed to $84.8 million. The company reaffirmed its full-year revenue target of $150 million to $180 million.
TradingKey
Thu, Aug 6
Hamilton Q2 2026 Earnings: Catastrophe Losses Cut Underwriting Profit
Hamilton Insurance Group’s Q2 2026 total revenue rose approximately 13.3% year over year to $839.6 million, while net premiums earned increased 14.6% to $586.0 million. Diluted EPS fell to $1.42 from $1.79 as $49.9 million of catastrophe losses, led by the Middle East conflict, pushed the combined ratio to 95.0% from 86.8% and reduced underwriting income to $29.1 million. International premium growth outpaced Bermuda, while $141.3 million of highlighted net investment income helped support profitability despite weaker underwriting results.
TradingKey
Thu, Aug 6
ICU Medical Q2 2026 earnings: Organic revenue rises 6% as guidance increases
ICU Medical’s Q2 2026 revenue rose 1% to $551.7 million, while organic revenue increased 6% after excluding the IV Solutions divestiture and currency effects. GAAP diluted EPS fell to $0.76 from $1.43 because the prior-year quarter included a $41.8 million business-sale gain, but adjusted EPS rose to $2.37 and adjusted EBITDA reached $110.0 million. Gross margin reached 43%, Infusion Systems led product-line growth, free cash flow improved to $61.7 million, and the company raised its fiscal 2026 guidance across GAAP and adjusted earnings measures.
TradingKey
Thu, Aug 6
CytoSorbents Q2 2026 earnings: Margins improve despite flat revenue
CytoSorbents’ Q2 2026 revenue was $9.6 million, essentially unchanged year over year, while diluted EPS moved to a $0.07 loss from $0.03 of earnings. Gross margin rose to 73% from 71%, and the operating loss narrowed 27% to $2.6 million as manufacturing efficiency and tighter costs improved underlying economics. However, foreign-currency effects drove a $4.4 million GAAP net loss, and unrestricted cash ended June at $4.4 million. Germany remained the main commercial drag, while DrugSorb-ATR regulatory work and the cash-flow breakeven objective remain central watchpoints.
TradingKey
Thu, Aug 6
MSC Income Q2 2026 earnings: Fair value gains lift NAV as NII falls
MSC Income Fund’s Q2 2026 total investment income was $35.7 million, essentially flat year over year, while GAAP net investment income fell 26% to $12.0 million, or $0.26 per share. Adjusted NII was $0.33 per share. A $19.0 million net fair value increase, including an $11.6 million gain on the Centre Technologies exit, lifted net assets from operations to $29.3 million and NAV to $16.51 per share. Investors should monitor non-accrual exposure, funding costs, the October 2026 notes maturity, and dividend coverage.TradingKey
Thu, Aug 6
Akamai Q2 2026 Earnings: Cloud Growth Came With Margin Pressure
Akamai’s Q2 2026 revenue increased 5% year over year to $1.100 billion, led by 39% growth in Cloud Infrastructure Services and 10% growth in security. GAAP diluted EPS fell 27% to $0.52 as GAAP operating margin contracted to 7% from 15%; non-GAAP EPS declined 8% to $1.59. Operating cash flow was $326 million, while capex reached 32% of revenue on an accrual basis. The company issued Q3 and full-year 2026 guidance and highlighted more than $2.8 billion of year-to-date multi-year cloud infrastructure contracts.
TradingKey
Thu, Aug 6
Dentsply Sirona Q2 2026 Earnings: Sales Decline as GAAP Margins Recover
Dentsply Sirona’s Q2 2026 net sales fell 4.1% to $898 million, while GAAP diluted EPS improved to $0.18 from a $0.22 loss a year earlier. Operating cash flow rose to $99 million from $48 million, helped by about $44 million of tariff refunds and better inventory and payables management. However, constant-currency sales declined 6.3%, led by weakness in Orthodontic and Implant Solutions, while the company maintained its 2026 net sales and adjusted EPS guidance.
TradingKey
Thu, Aug 6
Progyny Q2 2026 Earnings: Margin Expansion Lifts Net Income
Progyny’s Q2 2026 revenue increased 5.3% to $350.5 million, while GAAP diluted EPS rose to $0.34 from $0.19 and gross margin expanded to 25.5% from 23.7%. Excluding $17.2 million of prior-year revenue from a large client that did not renew, revenue grew 11.0%. Fertility benefit revenue outpaced pharmacy growth, and lower stock-based compensation helped lift net income to $28.1 million. Operating cash flow was $50.4 million. Progyny guided to 2026 revenue of $1.360 billion to $1.385 billion and adjusted EBITDA of $233 million to $240 million.
TradingKey
Thu, Aug 6
Full House Resorts Q2 2026 earnings: Casino ramp-up lifts revenue and EBITDA
Full House Resorts’ Q2 2026 revenue increased 5.6% year over year to $78.1 million, while diluted loss per share narrowed to $0.24 from $0.29. Adjusted EBITDA rose 19.5% to $13.3 million as American Place set property records and Chamonix/Bronco Billy’s moved closer to break-even. GAAP operating income reached $2.3 million, versus a small loss a year earlier, but $10.8 million of net interest expense kept the company at an $8.7 million net loss. Key follow-up issues include refinancing, construction financing, and property ramp-up execution.
TradingKey
Thu, Aug 6
nLIGHT Q2 2026 earnings: Product revenue drives a record quarter
nLIGHT’s Q2 2026 revenue rose 33.8% to a record $82.6 million, led by 45% growth in Products revenue to $59.4 million. Gross margin improved 120 basis points to 31.1%, while GAAP net loss narrowed to $1.3 million, or $0.02 per diluted share. Adjusted EBITDA reached $10.7 million. Q3 guidance calls for $63 million to $73 million in revenue after supply-chain constraints shifted about $17 million of expected product shipments into future quarters. Aerospace and Defense revenue grew approximately 41% and remained the largest end market.
TradingKey
Thu, Aug 6
Karman Q2 FY2026 Earnings: Revenue Rises 58% as Backlog Reaches $1.3 Billion
Karman Space & Defense’s fiscal Q2 2026 revenue rose 58.2% to $182.1 million, while diluted EPS increased to $0.11 from $0.05 and net income reached $14.0 million. Organic growth was 24.4%, quarterly bookings approached $500 million, and backlog climbed to $1.3 billion. GAAP margins improved, but adjusted EBITDA margin slipped to 30.0% from 30.7%. Karman also raised fiscal 2026 guidance to $730 million-$745 million in revenue and $215.0 million-$222.5 million in adjusted EBITDA.
TradingKey
Thu, Aug 6
Featured Tools
Top News
Meta Q3 Net Profit Surges 264% YoY, Raises Full-Year Capex Slightly; Shares Briefly Rise Over 4% After Hours
US Stocks Close: Nasdaq Drops 2.6%, SOX Falls Over 6%; Jensen Huang's Remarks on Capital Shortage Spark Financing Concerns, Meta Drops 7% After Earnings
Bloom Energy Q3 Revenue Up 138% YoY, EPS Swings to Profit, But Shares Tumble 7% After Hours
US Stocks Close: Nasdaq Gains Over 1%, Philadelphia Semiconductor Index Rises Nearly 2%; Tech Stocks Strengthen, SpaceX Gains Nearly 8% Post-Earnings
Memory Stocks Fall Over 4% as Micron Drops Below $900, Risking Another 16% Fall to Retest Lows
